Bayer, Indena Enter Licensing Agreement

WEST HAVEN, Conn.--Milan-based Indena has entered into a licensing agreement with the Bayer Corp.'s Pharmaceutical Division for its IDN 5109 anti-cancer compound and its derivatives. Indena has granted Bayer the exclusive rights to the ingredient.

Indena researches, manufactures and markets active principles derived from plants for use in pharmaceutical, health food and cosmetics applications. The agreement will be effective once the United States government has granted approval.